Cytek Biosciences (CTKB) Equity Average (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Equity Average data on file, last reported at $334.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 13.67% year-over-year to $334.7 million; the trailing twelve-month figure through Mar 2026 stood at $334.7 million (down 13.67% YoY), and the FY2025 full-year result was $368.7 million, down 6.51% from the prior year.
• Equity Average for Q1 2026 stood at $334.7 million, down from $360.2 million in the prior quarter.
• Across five years, Equity Average topped out at $424.5 million in Q1 2023 and bottomed at $334.7 million in Q1 2026.
• The 5-year median for Equity Average is $392.8 million (2024), against an average of $395.5 million.
• The widest annual swing landed in 2022, when Equity Average surged 8380.94%; it then slipped 13.67% in 2026.
• A 5-year view of Equity Average shows it stood at $421.0 million in 2022, then decreased by 3.97% to $404.3 million in 2023, then dropped by 3.39% to $390.6 million in 2024, then dropped by 7.79% to $360.2 million in 2025, then retreated by 7.07% to $334.7 million in 2026.
• The last three Equity Average figures came in at $334.7 million (Q1 2026), $360.2 million (Q4 2025), and $378.1 million (Q3 2025), per Business Quant data.

Peer Comparison